Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2009

View Archived Issues

Influenza A/H1N1 vaccine evaluated in a series of phase II trials by sanofi-aventis and NIAID

Novel oncolytic compounds claimed by Korean scientists

Hematologic improvement seen with Telintra in myelodysplastic syndrome patients

Data from phase III studies show efficacy of roflumilast in chronic obstructive pulmonary disease

Peregrine reports advances in bavituximab clinical program

MediGene obtains marketing authorization for Veregen in Germany

Vical receives USD 2.5 million payment for funding of Allovectin-7 trial

Biovista reports results from preclinical trial of BVA-201 in multiple sclerosis

PRO-040201 to be evaluated by Tekmira in phase I trial in patients with hypercholesterolemia

Chelsea Therapeutics achieves target enrollment in second pivotal phase III droxidopa trial

Intranasal influenza vaccination with NB-1008 safe in rabbits

Sulopenem and its prodrug evaluated in healthy volunteers

PH-10 aqueous hydrogel to be assessed in plaque psoriasis in phase II trial

AstraZeneca discloses Janus kinase inhibitors for the treatment of cancer

Anti-staphylococcal activity of novel antimicrobial XF-70 described during the ICAAC meeting

Cleveland BioLabs and Zhejiang Hisun enter license agreement for CBLB-612

BACE1 inhibitors for the treatment of cognitive disorders discovered by Janssen

NPY Y5 antagonists in development at GSK for the treatment of eating disorders

Chinese scientists describe a novel series of anti-HIV agents

Oramed commences human clinical trials for oral GLP-1 analogue

FDA Advisory Committee votes favorably for Cervarix

ImmunoCellular Therapeutics enters into agreement with Roche for ICT-69 antibody

Xoma and Arana Therapeutics form antibody discovery collaboration

Galapagos initiates second phase I GLPG-0259 trial in rheumatoid arthritis

Cumberland launches intravenous ibuprofen in the U.S. for pain and fever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...